Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors
Research output: Contribution to journal › Journal article › Research › peer-review
Cholangiocarcinoma is a heterogeneous disease with a poor outcome that accounts for 5%-10% of primary liver cancers. We characterized its genomic and genetic features and associated these with patient responses to therapy.
| Original language | English |
|---|---|
| Journal | Gastroenterology |
| Volume | 142 |
| Issue number | 4 |
| Pages (from-to) | 1021-1031.e15 |
| ISSN | 0016-5085 |
| DOIs | |
| Publication status | Published - Apr 2012 |
| Externally published | Yes |
- Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Belgium, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Blotting, Western, Cell Line, Tumor, Cell Proliferation, Chi-Square Distribution, Cholangiocarcinoma, Cluster Analysis, Female, Gene Expression Profiling, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Individualized Medicine, Kaplan-Meier Estimate, Laser Capture Microdissection, Male, Middle Aged, Molecular Targeted Therapy, Mutation, Oligonucleotide Array Sequence Analysis, Patient Selection, Phenotype, Prognosis, Proportional Hazards Models, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Proto-Oncogene Proteins B-raf, Queensland, Quinazolines, Receptor, Epidermal Growth Factor, Risk Assessment, Risk Factors, Survival Rate, Time Factors, Tumor Microenvironment, United States, ras Proteins
Research areas
ID: 97138839